Rep. Mike Lawler, a Republican from New York, has called for the United States to assert greater control over its prescription drug industry, citing risks posed by China’s growing influence in the sector. During an appearance on ‘One Nation,’ Lawler discussed the Trump administration’s ongoing efforts to combat drug cartels and safeguard national interests, framing the issue as a matter of both economic and national security. Lawler argues that China’s regulatory framework and potential interference in pharmaceutical supply chains could undermine U.S. healthcare systems and strategic assets.
The congressman’s comments come amid heightened scrutiny of foreign involvement in critical industries, particularly following recent reports of Chinese state-backed companies expanding their presence in U.S. markets. While Lawler did not specify immediate policy actions, his remarks align with a broader conservative push for stronger domestic control over key sectors and heightened scrutiny of foreign entities. Analysts suggest that Lawler’s stance could influence future legislative debates on drug regulation and international trade policies.